European Archives - Page 910 of 981 - European Medical Journal

Continue
EMJ
23 Jul 2015

ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…
EMJ
23 Jul 2015

Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…
EMJ
23 Jul 2015

Towards precision medicine in cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 2015–2016 term, Julie M. Vose, MD, MBA, FASCO…
EMJ
23 Jul 2015

Immunotherapy and targeted therapies in melanoma at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, reviews…
EMJ
23 Jul 2015

Focus on geriatric oncology at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lodovico Balducci, MD, of Moffitt Cancer Center, Tampa, FL, explains the current…
EMJ
23 Jul 2015

PFS and correlative biomarker analysis from the phase 3 coBRIM study

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…
EMJ
23 Jul 2015

Individualising therapy in older patients with breast cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, discusses…
EMJ
23 Jul 2015

Maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…
EMJ
23 Jul 2015

Molecular signatures in breast cancer

At the 9th European Breast Cancer Conference (EBCC), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, and Daniel Rea, MBBS, BSc, PhD…
EMJ
23 Jul 2015

Phase 3 CheckMate 067 trial of nivolumab in untreated advanced melanoma

Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, disusses the results of the CheckMate 067 trial, a phase 3 trial of nivolumab…